{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:45:28Z","timestamp":1792788328328,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T00:00:00Z","timestamp":1736812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Oxyrane"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Fluids Barriers CNS"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Iduronate-2-sulfatase (IDS) deficiency (MPS II; Hunter syndrome) is a disorder that exhibits peripheral and CNS pathology. The blood brain barrier (BBB) prevents systemic enzyme replacement therapy (ERT) from alleviating CNS pathology. We aimed to enable brain delivery of systemic ERT by using molecular BBB-Trojans targeting endothelial transcytosis receptors. Methods: Single-domain antibody (sdAb)-enzyme fusion protein constructs were prepared in\n                      <jats:italic>Yarrowia lipolytica<\/jats:italic>\n                      . sdAb affinity and BBB permeability were characterized using SPR and an in vitro rodent BBB assay, respectively. In vivo pharmacokinetic (PK) analysis was performed in rats. Quantification of fusion protein amounts were performed using LC-MS.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Fusion proteins consisting of IDS and BBB-transmigrating sdAbs, albumin binding sdAbs or human serum albumin (HSA) were evaluated for their in vitro BBB permeability. IGF1R3H5-IDS was selected for in vivo PK analysis in rats. IDS and IGF1R3H5-IDS exhibited very short (&lt;\u200910\u00a0min) serum half-life (t\n                      <jats:sub>1\/2\u03b1<\/jats:sub>\n                      ), while constructs containing either HSA or anti-serum albumin sdAbs (R28 or M79) showed 8\u201311 fold increases in the area under the curve (AUC) in serum. CSF analysis indicated that IGF1R3H5 increased brain exposure by 9 fold (AUC) and constructs containing HSA or R28 exhibited 42\u201352 fold increases. Quantitation of brain levels confirmed the increased and sustained delivery of IDS to the brain of HSA- and R28-containing constructs. Lastly, analysis of brain fractions demonstrated that the increases in brain tissue were due to parenchymal delivery without fusion protein accumulation in brain vessels.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      These results demonstrate the utility of IGF1R-targeting sdAbs to effect brain delivery of lysosomal enzymes, as well as the utility of serum albumin-targeting sdAbs in t\n                      <jats:sub>1\/2<\/jats:sub>\n                      extension, to increase brain delivery of rapidly cleared enzymes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12987-024-00617-6","type":"journal-article","created":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T07:30:50Z","timestamp":1736839850000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["In vivo brain delivery of BBB-enabled iduronate 2-sulfatase in rats"],"prefix":"10.1186","volume":"22","author":[{"given":"Will J.","family":"Costain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arsalan S.","family":"Haqqani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Greg","family":"Hussack","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk","family":"van Faassen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Lessard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Binbing","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Brunette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dao","family":"Ly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennyfer","family":"Bultinck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Geysens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gwenda","family":"Pynaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Piens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Ryckaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck","family":"Fudalej","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Vervecken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danica","family":"Stanimirovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,14]]},"reference":[{"key":"617_CR1","doi-asserted-by":"crossref","unstructured":"Parenti G, Andria G, Ballabio A. Lysosomal storage diseases: from pathophysiology to therapy. Annu Rev Med [Internet]. 2015;66:471\u201386. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25587658","DOI":"10.1146\/annurev-med-122313-085916"},{"key":"617_CR2","doi-asserted-by":"crossref","unstructured":"Begley D, Pontikis C, Scarpa M. Lysosomal Storage Diseases and the Blood-Brain Barrier. Curr Pharm Des [Internet]. 2008;14:1566\u201380. Available from: http:\/\/www.eurekaselect.com\/openurl\/content.php?genre=article&issn=1381-6128&volume=14&issue=16&spage=1566","DOI":"10.2174\/138161208784705504"},{"key":"617_CR3","doi-asserted-by":"crossref","unstructured":"Edelmann MJ, Maegawa GHB. CNS-Targeting Therapies for Lysosomal Storage Diseases: Current Advances and Challenges. Front Mol Biosci [Internet]. 2020;7:559804. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33304924","DOI":"10.3389\/fmolb.2020.559804"},{"key":"617_CR4","doi-asserted-by":"crossref","unstructured":"Sands MS, Vogler CA, Ohlemiller KK, Roberts MS, Grubb JH, Levy B et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem [Internet]. 2001;276:43160\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11562370","DOI":"10.1074\/jbc.M107778200"},{"key":"617_CR5","doi-asserted-by":"crossref","unstructured":"Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ. Structure and function of the blood-brain barrier. Neurobiol Dis [Internet]. 2010;37:13\u201325. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19664713","DOI":"10.1016\/j.nbd.2009.07.030"},{"key":"617_CR6","doi-asserted-by":"publisher","unstructured":"Stanimirovic DB, Sandhu JK, Costain WJ. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier. BioDrugs [Internet]. 2018;32:547\u201359. Available from: http:\/\/link.springer.com\/https:\/\/doi.org\/10.1007\/s40259-018-0309-y","DOI":"10.1007\/s40259-018-0309-y"},{"key":"617_CR7","doi-asserted-by":"crossref","unstructured":"Okuyama T, Eto Y, Sakai N, Nakamura K, Yamamoto T, Yamaoka M et al. A Phase 2\/3 Trial of Pabinafusp Alfa, IDS Fused with Anti-Human Transferrin Receptor Antibody, Targeting Neurodegeneration in MPS-II. Mol Ther [Internet]. 2020; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33038326","DOI":"10.1016\/j.ymthe.2020.09.039"},{"key":"617_CR8","unstructured":"Ullman JC, Arguello A, Getz JA, Bhalla A, Mahon CS, Wang J et al. Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice. Sci Transl Med [Internet]. 2020;12. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32461331"},{"key":"617_CR9","doi-asserted-by":"crossref","unstructured":"Webster CI, Caram-Salas N, Haqqani AS, Thom G, Brown L, Rennie K et al. Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1. FASEB J [Internet]. 2016 [cited 2016 Feb 4];30:1927\u201340. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26839377","DOI":"10.1096\/fj.201500078"},{"key":"617_CR10","doi-asserted-by":"crossref","unstructured":"Muruganandam A, Tanha J, Narang S, Stanimirovic D. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium. FASEB J [Internet]. 2002;16:240\u20132. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11772942","DOI":"10.1096\/fj.01-0343fje"},{"key":"617_CR11","first-page":"42","volume-title":"Insulin-like growth factor 1 receptor -specific antibodies and uses thereof","author":"DB Stanimirovic","year":"2017","unstructured":"Stanimirovic DB, Kemmerich K, Haqqani AS, Sulea T, Arbabi-Ghahroudi M, Massie B, et al. Insulin-like growth factor 1 receptor -specific antibodies and uses thereof. United States: USPTO; 2017. p. 42."},{"key":"617_CR12","doi-asserted-by":"publisher","unstructured":"Abulrob A, Sprong H, Van Bergen P, Stanimirovic D. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells. J Neurochem [Internet]. 2005;95:1201\u201314. Available from: https:\/\/doi.org\/10.1111\/j.1471-4159.2005.03463.x","DOI":"10.1111\/j.1471-4159.2005.03463.x"},{"key":"617_CR13","doi-asserted-by":"crossref","unstructured":"Sheff J, Wang P, Xu P, Arbour M, Masson L, van Faassen H et al. Defining the epitope of a blood-brain barrier crossing single domain antibody specific for the type 1 insulin-like growth factor receptor. Sci Rep [Internet]. 2021;11:4284. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33608571","DOI":"10.1038\/s41598-021-83198-w"},{"key":"617_CR14","doi-asserted-by":"crossref","unstructured":"Henry KA, Tanha J, Hussack G. Identification of cross-reactive single-domain antibodies against serum albumin using next-generation DNA sequencing. Protein Eng Des Sel [Internet]. 2015 [cited 2016 Oct 24];28:379\u201383. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26319004","DOI":"10.1093\/protein\/gzv039"},{"key":"617_CR15","doi-asserted-by":"crossref","unstructured":"van Faassen H, Ryan S, Henry KA, Raphael S, Yang Q, Rossotti MA et al. Serum albumin-binding VH Hs with variable pH sensitivities enable tailored half-life extension of biologics. FASEB J [Internet]. 2020;34:8155\u201371. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32342547","DOI":"10.1096\/fj.201903231R"},{"key":"617_CR16","doi-asserted-by":"crossref","unstructured":"Tanha J, Muruganandam A, Stanimirovic D. Phage display technology for identifying specific antigens on brain endothelial cells. Methods Mol Med [Internet]. 2003;89:435\u201349. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/12958438","DOI":"10.1385\/1-59259-419-0:435"},{"key":"617_CR17","doi-asserted-by":"crossref","unstructured":"B\u00e9langer K, Iqbal U, Tanha J, MacKenzie R, Moreno M, Stanimirovic D. Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases. Antibodies (Basel, Switzerland) [Internet]. 2019;8. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31544833","DOI":"10.3390\/antib8020027"},{"key":"617_CR18","doi-asserted-by":"crossref","unstructured":"Sodja C, Callaghan D, Haqqani AS, Stanimirovic DB, Costain WJ, Jezierski A. Immunoassay for Quantitative Detection of Antibody Transcytosis Across the Blood-Brain Barrier In Vitro. Methods Mol Biol [Internet]. 2022;2549:345\u201357. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35218529","DOI":"10.1007\/7651_2021_456"},{"key":"617_CR19","doi-asserted-by":"crossref","unstructured":"Ribecco-Lutkiewicz M, Sodja C, Haukenfrers J, Haqqani AS, Ly D, Zachar P et al. A novel human induced pluripotent stem cell blood-brain barrier model: Applicability to study antibody-triggered receptor-mediated transcytosis. Sci Rep [Internet]. 2018;8:1873. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/29382846","DOI":"10.1038\/s41598-018-19522-8"},{"key":"617_CR20","doi-asserted-by":"publisher","unstructured":"Ying T, Chen W, Gong R, Feng Y, Dimitrov DS. Soluble monomeric IgG1 Fc. J Biol Chem [Internet]. 2012;287:19399\u2013408. Available from: http:\/\/www.jbc.org\/lookup\/doi\/https:\/\/doi.org\/10.1074\/jbc.M112.368647","DOI":"10.1074\/jbc.M112.368647"},{"key":"617_CR21","doi-asserted-by":"publisher","unstructured":"Stojanovic F, Taktek M, Khieu NH, Huang J, Jiang S, Rennie K et al. NMR analysis of the correlation of metabolic changes in blood and cerebrospinal fluid in Alzheimer model male and female mice. Ginsberg SD, editor. PLoS One [Internet]. 2021;16:e0250568. Available from: https:\/\/doi.org\/10.1371\/journal.pone.0250568","DOI":"10.1371\/journal.pone.0250568"},{"key":"617_CR22","doi-asserted-by":"crossref","unstructured":"Wikman-Jorgensen PE, L\u00f3pez Amor\u00f3s A, Peris Garc\u00eda J, Esteve Atienzar PJ, Ca\u00f1izares Navarro R, Asensio Tom\u00e1s ML et al. Enzyme replacement therapy for the treatment of Hunter disease: A systematic review with narrative synthesis and meta-analysis. Mol Genet Metab [Internet]. 2020;131:206\u201310. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32773276","DOI":"10.1016\/j.ymgme.2020.07.005"},{"key":"617_CR23","doi-asserted-by":"crossref","unstructured":"Muenzer J, Botha J, Harmatz P, Giugliani R, Kampmann C, Burton BK. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS). Orphanet J Rare Dis [Internet]. 2021;16:456. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34717704","DOI":"10.1186\/s13023-021-02052-4"},{"key":"617_CR24","doi-asserted-by":"crossref","unstructured":"Muenzer J, Bodamer O, Burton B, Clarke L, Frenking GS, Giugliani R et al. The role of enzyme replacement therapy in severe Hunter syndrome-an expert panel consensus. Eur J Pediatr [Internet]. 2012 [cited 2016 Feb 13];171:181\u20138. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=3249184&tool=pmcentrez&rendertype=abstract","DOI":"10.1007\/s00431-011-1606-3"},{"key":"617_CR25","doi-asserted-by":"crossref","unstructured":"Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S et al. A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med [Internet]. 2016 [cited 2016 Feb 13];18:73\u201381. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25834948","DOI":"10.1038\/gim.2015.36"},{"key":"617_CR26","doi-asserted-by":"crossref","unstructured":"Daneman R, Prat A. The blood-brain barrier. Cold Spring Harb Perspect Biol [Internet]. 2015;7:a020412. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25561720","DOI":"10.1101\/cshperspect.a020412"},{"key":"617_CR27","doi-asserted-by":"crossref","unstructured":"Terstappen GC, Meyer AH, Bell RD, Zhang W. Strategies for delivering therapeutics across the blood\u2013brain barrier. Nat Rev Drug Discov [Internet]. 2021;20:362\u201383. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/33649582","DOI":"10.1038\/s41573-021-00139-y"},{"key":"617_CR28","doi-asserted-by":"crossref","unstructured":"Muenzer J, Hendriksz CJ, Stein MB, Fan Z, Kearney S, Horton J et al. A long-term extension study evaluating intrathecal idursulfase-IT in children with Hunter syndrome and cognitive impairment. Mol Genet Metab [Internet]. 2017;120:S99\u2013100. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216306680","DOI":"10.1016\/j.ymgme.2016.11.249"},{"key":"617_CR29","doi-asserted-by":"crossref","unstructured":"Muenzer J, Vijayaraghavan S, Stein M, Kearney S, Wu Y, Alexanderian D. Long-term open-label phase I\/II extension study of intrathecal idursulfase-IT in the treatment of neuronopathic mucopolysaccharidosis II. Genet Med [Internet]. 2022; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35588317","DOI":"10.1016\/j.gim.2022.04.002"},{"key":"617_CR30","doi-asserted-by":"crossref","unstructured":"Sato Y, Minami K, Hirato T, Tanizawa K, Sonoda H, Schmidt M. Drug delivery for neuronopathic lysosomal storage diseases: evolving roles of the blood brain barrier and cerebrospinal fluid. Metab Brain Dis [Internet]. 2022; Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35088290","DOI":"10.1007\/s11011-021-00893-3"},{"key":"617_CR31","doi-asserted-by":"crossref","unstructured":"Bellavance M-A, Blanchette M, Fortin D. Recent advances in blood-brain barrier disruption as a CNS delivery strategy. AAPS J [Internet]. 2008;10:166\u201377. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18446517","DOI":"10.1208\/s12248-008-9018-7"},{"key":"617_CR32","doi-asserted-by":"crossref","unstructured":"Poon C, McMahon D, Hynynen K. Noninvasive and targeted delivery of therapeutics to the brain using focused ultrasound. Neuropharmacology [Internet]. 2017;120:20\u201337. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26907805","DOI":"10.1016\/j.neuropharm.2016.02.014"},{"key":"617_CR33","doi-asserted-by":"crossref","unstructured":"Boado RJ, Zhang YYY, Zhang YYY, Xia C-F, Wang Y, Pardridge WM. Genetic engineering of a lysosomal enzyme fusion protein for targeted delivery across the human blood-brain barrier. Biotechnol Bioeng [Internet]. 2008 [cited 2016 Feb 18];99:475\u201384. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17680664","DOI":"10.1002\/bit.21602"},{"key":"617_CR34","doi-asserted-by":"crossref","unstructured":"Boado RJ, Hui EK-W, Lu JZ, Zhou Q-H, Pardridge WM. Reversal of lysosomal storage in brain of adult MPS-I mice with intravenous Trojan horse-iduronidase fusion protein. Mol Pharm [Internet]. 2011 [cited 2016 Feb 18];8:1342\u201350. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21667973","DOI":"10.1021\/mp200136x"},{"key":"617_CR35","doi-asserted-by":"crossref","unstructured":"Boado RJ, Hui EK-W, Lu JZ, Sumbria RK, Pardridge WM. Blood-brain barrier molecular trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug Chem [Internet]. 2013 [cited 2016 Jan 31];24:1741\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/24059813","DOI":"10.1021\/bc400319d"},{"key":"617_CR36","doi-asserted-by":"crossref","unstructured":"Zhou Q-H, Boado RJ, Lu JZ, Hui EK-W, Pardridge WM. Brain-penetrating IgG-iduronate 2-sulfatase fusion protein for the mouse. Drug Metab Dispos [Internet]. 2012;40:329\u201335. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22065691","DOI":"10.1124\/dmd.111.042903"},{"key":"617_CR37","doi-asserted-by":"crossref","unstructured":"Giugliani R, Martins AM, Okuyama T, Eto Y, Sakai N, Nakamura K et al. Enzyme Replacement Therapy with Pabinafusp Alfa for Neuronopathic Mucopolysaccharidosis II: An Integrated Analysis of Preclinical and Clinical Data. Int J Mol Sci [Internet]. 2021;22. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34681597","DOI":"10.20944\/preprints202109.0192.v1"},{"key":"617_CR38","doi-asserted-by":"crossref","unstructured":"Yamamoto R, Yoden E, Tanaka N, Kinoshita M, Imakiire A, Hirato T et al. Nonclinical safety evaluation of pabinafusp alfa, an anti-human transferrin receptor antibody and iduronate-2-sulfatase fusion protein, for the treatment of neuronopathic mucopolysaccharidosis type II. Mol Genet Metab Reports [Internet]. 2021;27:100758. Available from: https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2214426921000525","DOI":"10.1016\/j.ymgmr.2021.100758"},{"key":"617_CR39","doi-asserted-by":"crossref","unstructured":"Tomita K, Okamoto S, Seto T, Hamazaki T, So S, Yamamoto T et al. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report. JIMD Rep [Internet]. 2021;62:9\u201314. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/34765392","DOI":"10.1002\/jmd2.12239"},{"key":"617_CR40","doi-asserted-by":"crossref","unstructured":"Alata W, Yogi A, Brunette E, Delaney CE, van Faassen H, Hussack G et al. Targeting insulin-like growth factor-1 receptor (IGF1R) for brain delivery of biologics. FASEB J [Internet]. 2022;36:e22208. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35192204","DOI":"10.1096\/fj.202101644R"},{"key":"617_CR41","doi-asserted-by":"crossref","unstructured":"Yogi A, Hussack G, van Faassen H, Haqqani AS, Delaney CE, Brunette E et al. Brain Delivery of IGF1R5, a Single-Domain Antibody Targeting Insulin-like Growth Factor-1 Receptor. Pharmaceutics [Internet]. 2022;14. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/35890347","DOI":"10.3390\/pharmaceutics14071452"},{"key":"617_CR42","doi-asserted-by":"crossref","unstructured":"Schuck P, Zhao H. The role of mass transport limitation and surface heterogeneity in the biophysical characterization of macromolecular binding processes by SPR biosensing. Methods Mol Biol [Internet]. 2010;627:15\u201354. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20217612","DOI":"10.1007\/978-1-60761-670-2_2"},{"key":"617_CR43","doi-asserted-by":"crossref","unstructured":"Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM. Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol Bioeng [Internet]. 2014 [cited 2016 Feb 18];111:2317\u201325. Available from: http:\/\/www.pubmedcentral.nih.gov\/articlerender.fcgi?artid=4176522&tool=pmcentrez&rendertype=abstract","DOI":"10.1002\/bit.25289"},{"key":"617_CR44","doi-asserted-by":"crossref","unstructured":"Garcia AR, DaCosta JM, Pan J, Muenzer J, Lamsa JC. Preclinical dose ranging studies for enzyme replacement therapy with idursulfase in a knock-out mouse model of MPS II. Mol Genet Metab [Internet]. 2007;91:183\u201390. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17459751","DOI":"10.1016\/j.ymgme.2007.03.003"},{"key":"617_CR45","doi-asserted-by":"publisher","unstructured":"Sohn YB, Cho SY, Park SW, Kim SJ, Ko A-R, Kwon E-K et al. Phase I\/II clinical trial of enzyme replacement therapy with idursulfase beta in patients with mucopolysaccharidosis II (Hunter Syndrome). Orphanet J Rare Dis [Internet]. BioMed Central; 2013 [cited 2017 Nov 21];8:42. Available from: http:\/\/ojrd.biomedcentral.com\/articles\/https:\/\/doi.org\/10.1186\/1750-1172-8-42","DOI":"10.1186\/1750-1172-8-42"},{"key":"617_CR46","doi-asserted-by":"crossref","unstructured":"Xie H, Chung J-K, Mascelli MA, McCauley TG. Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. PLoS One [Internet]. 2015;10:e0122453. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/25836678","DOI":"10.1371\/journal.pone.0122453"},{"key":"617_CR47","doi-asserted-by":"crossref","unstructured":"Whiteman DA, Kimura A. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future. Drug Des Devel Ther [Internet]. 2017;11:2467\u201380. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/28860717","DOI":"10.2147\/DDDT.S139601"},{"key":"617_CR48","doi-asserted-by":"crossref","unstructured":"Shen J-S, Busch A, Day TS, Meng X-L, Yu CI, Dabrowska-Schlepp P et al. Mannose receptor-mediated delivery of moss-made \u03b1-galactosidase A efficiently corrects enzyme deficiency in Fabry mice. J Inherit Metab Dis [Internet]. 2016;39:293\u2013303. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/26310963","DOI":"10.1007\/s10545-015-9886-9"},{"key":"617_CR49","doi-asserted-by":"crossref","unstructured":"Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ, Kimura A. A phase I\/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab [Internet]. 2007 [cited 2016 Feb 29];90:329\u201337. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/17185020","DOI":"10.1016\/j.ymgme.2006.09.001"},{"key":"617_CR50","unstructured":"Fang H, Stanimirovic D, Haqqani A, Costain W, Hussack G. Blood-Brain Barrier Transmigrating Therapeutic Compounds and Uses Thereof [Internet]. Canada; 2019. Available from: https:\/\/www.ic.gc.ca\/opic-cipo\/cpd\/eng\/patent\/3098162\/summary.html?type=number_search&tabs1Index=tabs1_1#tabs1_1"},{"key":"617_CR51","doi-asserted-by":"crossref","unstructured":"Cadaoas J, Boyle G, Jungles S, Cullen S, Vellard M, Grubb JH et al. Vestronidase alfa: Recombinant human \u03b2-glucuronidase as an enzyme replacement therapy for MPS VII. Mol Genet Metab [Internet]. 2020;130:65\u201376. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32192868","DOI":"10.1016\/j.ymgme.2020.02.009"},{"key":"617_CR52","doi-asserted-by":"crossref","unstructured":"Gustavsson S, Ohlin Sj\u00f6str\u00f6m E, Tjernberg A, Janson J, Westermark U, Andersson T et al. Intravenous delivery of a chemically modified sulfamidase efficiently reduces heparan sulfate storage and brain pathology in mucopolysaccharidosis IIIA mice. Mol Genet Metab reports [Internet]. 2019;21:100510. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31528541","DOI":"10.1016\/j.ymgmr.2019.100510"},{"key":"617_CR53","doi-asserted-by":"crossref","unstructured":"Janson J, Andersson G, Bergquist L, Eriksson M, Folgering JHA. Impact of chemical modification of sulfamidase on distribution to brain interstitial fluid and to CSF after an intravenous administration in awake, freely-moving rats. Mol Genet Metab reports [Internet]. 2020;22:100554. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/31908953","DOI":"10.1016\/j.ymgmr.2019.100554"},{"key":"617_CR54","unstructured":"Vervecken W, Ryckaert S, Valesvska AV. Production of catalytically active type i sulfatase [Internet]. GB: World Intellectual Property Organization; 2014. p. 129. Available from: https:\/\/patents.google.com\/patent\/WO2014136065A2\/en?oq=WO2014136065A2"},{"key":"617_CR55","doi-asserted-by":"crossref","unstructured":"Tiels P, Baranova E, Piens K, De Visscher C, Pynaert G, Nerinckx W et al. A bacterial glycosidase enables mannose-6-phosphate modification and improved cellular uptake of yeast-produced recombinant human lysosomal enzymes. Nat Biotechnol [Internet]. 2012;30:1225\u201331. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23159880","DOI":"10.1038\/nbt.2427"},{"key":"617_CR56","doi-asserted-by":"crossref","unstructured":"De Pourcq K, Vervecken W, Dewerte I, Valevska A, Van Hecke A, Callewaert N. Engineering the yeast Yarrowia lipolytica for the production of therapeutic proteins homogeneously glycosylated with Man\u2088GlcNAc\u2082 and Man\u2085GlcNAc\u2082. Microb Cell Fact [Internet]. 2012;11:53. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/22548968","DOI":"10.1186\/1475-2859-11-53"},{"key":"617_CR57","doi-asserted-by":"crossref","unstructured":"Garberg P, Ball M, Borg N, Cecchelli R, Fenart L, Hurst RD et al. In vitro models for the blood-brain barrier. Toxicol In Vitro [Internet]. 2005 [cited 2016 Mar 3];19:299\u2013334. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/15713540","DOI":"10.1016\/j.tiv.2004.06.011"},{"key":"617_CR58","doi-asserted-by":"crossref","unstructured":"Haqqani AS, Caram-Salas N, Ding W, Brunette E, Delaney CE, Baumann E et al. Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method. Mol Pharm [Internet]. 2013 [cited 2016 Mar 10];10:1542\u201356. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/23150993","DOI":"10.1021\/mp3004995"},{"key":"617_CR59","doi-asserted-by":"crossref","unstructured":"Artursson P, Karlsson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem Biophys Res Commun [Internet]. 1991 [cited 2016 Mar 30];175:880\u20135. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/1673839","DOI":"10.1016\/0006-291X(91)91647-U"},{"key":"617_CR60","doi-asserted-by":"crossref","unstructured":"Nirogi R, Kandikere V, Mudigonda K, Bhyrapuneni G, Muddana N, Saralaya R et al. A simple and rapid method to collect the cerebrospinal fluid of rats and its application for the assessment of drug penetration into the central nervous system. J Neurosci Methods [Internet]. 2009 [cited 2016 Mar 29];178:116\u20139. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/19109998","DOI":"10.1016\/j.jneumeth.2008.12.001"},{"key":"617_CR61","doi-asserted-by":"crossref","unstructured":"Fluttert M, Dalm S, Oitzl MS. A refined method for sequential blood sampling by tail incision in rats. Lab Anim [Internet]. 2000 [cited 2016 Mar 10];34:372\u20138. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/11072857","DOI":"10.1258\/002367700780387714"},{"key":"617_CR62","doi-asserted-by":"crossref","unstructured":"Haqqani AS, Kelly JF, Stanimirovic DB. Quantitative protein profiling by mass spectrometry using isotope-coded affinity tags. Methods Mol Biol [Internet]. 2008\/03\/29. 2008;439:225\u201340. Available from: http:\/\/www.ncbi.nlm.nih.gov\/entrez\/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_uids=18370107","DOI":"10.1007\/978-1-59745-188-8_16"}],"container-title":["Fluids and Barriers of the CNS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-024-00617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12987-024-00617-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12987-024-00617-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T07:31:18Z","timestamp":1736839878000},"score":1,"resource":{"primary":{"URL":"https:\/\/fluidsbarrierscns.biomedcentral.com\/articles\/10.1186\/s12987-024-00617-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,14]]},"references-count":62,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["617"],"URL":"https:\/\/doi.org\/10.1186\/s12987-024-00617-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5405193\/v1","asserted-by":"object"}]},"ISSN":["2045-8118"],"issn-type":[{"value":"2045-8118","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,14]]},"assertion":[{"value":"6 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conduced at the National Research Council and prior ethical approval for the studies was obtained from the NRC Animal Care Committee. The NRC maintains active certification by the Canadian Council on Animal Care (CCAC) and conforms to their guidelines pertaining to research ethics involving rats. All studies described herein comply with the ARRIVE guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7"}}